The Queen Bey’s father, Mathew Knowles is gearing up to focus on his teaching career.
The Queen Bey’s father, Mathew Knowles is gearing up to focus on his teaching career.
FORM 8.5 (EPT/RI) PUBLIC DEALING DISCLOSURE BY AN EXEMPT PRINCIPAL TRADER WITH RECOGNISED INTERMEDIARY STATUS DEALING IN A CLIENT-SERVING CAPACITYRule 8.5 of the Takeover Code (the “Code”) 1. KEY INFORMATION (a) Name of exempt principal trader:Shore Capital Stockbrokers Ltd(b) Name of offeror/offeree in relation to whose relevant securities this form relates: Use a separate form for each offeror/offereeNucleus Financial Group PLC(c) Name of the party to the offer with which exempt principal trader is connected:Nucleus Financial Group PLC(d) Date dealing undertaken:13 April 2021(e) Has the EPT previously disclosed, or is it today disclosing, under the Code in respect of any other party to this offer?No 2. DEALINGS BY THE EXEMPT PRINCIPAL TRADER (a) Purchases and sales Class of relevant securityPurchases/ sales Total number of securitiesHighest price per unit paid/receivedLowest price per unit paid/receivedOrdinaryPurchases6,687185p185p (b) Derivatives transactions (other than options) Class of relevant securityProduct descriptione.g. CFDNature of dealinge.g. opening/closing a long/short position, increasing/reducing a long/short positionNumber of reference securitiesPrice per unit (c) Options transactions in respect of existing securities (i) Writing, selling, purchasing or varying Class of relevant securityProduct description e.g. call optionWriting, purchasing, selling, varying etc.Number of securities to which option relatesExercise price per unitTypee.g. American, European etc.Expiry dateOption money paid/ received per unit (ii) Exercising Class of relevant securityProduct descriptione.g. call optionNumber of securitiesExercise price per unit (d) Other dealings (including subscribing for new securities) Class of relevant securityNature of dealinge.g. subscription, conversionDetailsPrice per unit (if applicable) The currency of all prices and other monetary amounts should be stated. Where there have been dealings in more than one class of relevant securities of the offeror or offeree named in 1(b), copy table 2(a), (b), (c) or (d) (as appropriate) for each additional class of relevant security dealt in. 3. OTHER INFORMATION (a) Indemnity and other dealing arrangements Details of any indemnity or option arrangement, or any agreement or understanding, formal or informal, relating to relevant securities which may be an inducement to deal or refrain from dealing entered into by the exempt principal trader making the disclosure and any party to the offer or any person acting in concert with a party to the offer:If there are no such agreements, arrangements or understandings, state “none” None (b) Agreements, arrangements or understandings relating to options or derivatives Details of any agreement, arrangement or understanding, formal or informal, between the exempt principal trader making the disclosure and any other person relating to:(i) the voting rights of any relevant securities under any option; or (ii) the voting rights or future acquisition or disposal of any relevant securities to which any derivative is referenced:If there are no such agreements, arrangements or understandings, state “none” None Date of disclosure:14/04/2021Contact name:Molly AdkinTelephone number:020 7647 8154 Public disclosures under Rule 8 of the Code must be made to a Regulatory Information Service and must also be emailed to the Takeover Panel at firstname.lastname@example.org. The Panel’s Market Surveillance Unit is available for consultation in relation to the Code’s dealing disclosure requirements on +44 (0)20 7638 0129. The Code can be viewed on the Panel’s website at www.thetakeoverpanel.org.uk.
The "Sourcing Software Market - Growth, Trends, COVID-19 Impact, and Forecasts (2021 - 2026)" report has been added to ResearchAndMarkets.com's offering.
(Bloomberg) -- Zhejiang Geely Holding Group Co. is considering raising about $1 billion to help expand its iconic British sports and racing automotive business Lotus Cars into the electric vehicles market in China, according to people familiar with the matter.Geely is working with advisers to sound out potential investor interest in a funding round that could value Lotus’s EV operations at about $5 billion, the people said, asking not to be identified because the matter is private.Separately from the fundraising, the Chinese company is also weighing an initial public offering of Lotus Cars, or just the British carmaker’s EV business, as soon as next year, the people said. A listing could value the entire business, including its combustion-driven sports and racing cars, at more than $15 billion, the people said.Geely Automobile Holdings Ltd. shares rose as much as 7.6% on Wednesday in their biggest intraday gain since Jan. 26. The stock closed 5% higher, outperforming a 1.4% increase in the benchmark Hang Seng Index.Chinese billionaire Li Shufu’s Geely, which also controls Sweden-based Volvo Car AB, purchased a stake in Group Lotus in 2017. It owns 51% of the company, including both Lotus Cars and consultancy Lotus Engineering, while Malaysia’s Etika Automotive Bhd. owns the remainder, according to a press release. Under Geely, Lotus in 2019 launched its all-electric Evija hypercar, a 1,972-horsepower coupe that costs about $2 million.Considerations are ongoing and details including size and timing could change, the people said. A Geely representative declined to comment. Representatives for Lotus didn’t immediately comment when contacted by Bloomberg News.Geely is seeking to expand into electric vehicles amid a booming market in countries including China. Polestar, the electric carmaker controlled by Volvo Car and its owner Geely, is exploring options for going public as soon as this year, Bloomberg News has reported.Investor mania over EV-related stocks has pushed the share prices of players including Nio Inc. and Xpeng Inc. to stratospheric levels. That intense interest has also spawned a wave of EV upstarts raising billions and racing to list via special-purpose acquisition companies. More than $180 billion has been raised globally through SPAC IPOs in the past 12 months, Bloomberg-compiled data show.(Updates with Geely Automobile share price in fourth paragraph.)For more articles like this, please visit us at bloomberg.comSubscribe now to stay ahead with the most trusted business news source.©2021 Bloomberg L.P.
The country music singer-songwriter was suspended indefinitely from his label in February.
Forecasts by Manufacturing Type (Outsourced, In-house), by Expression Platform (Mammalian Cell Cultures, Microbial Fermentations, Others), by Application (Vaccines, MABs, Insulin Analogues, Interferon Therapies, Human Growth Hormones, Other Therapeutic Areas) AND Regional and Leading National Market Analysis PLUS Analysis of Leading Biological Drug API Manufacturing Companies AND COVID-19 Recovery Scenarios.New York, April 14, 2021 (GLOBE NEWSWIRE) -- Reportlinker.com announces the release of the report "Biological Drug API Manufacturing Services Market Report 2021-2031" - https://www.reportlinker.com/p06058469/?utm_source=GNW Biological Drug API Manufacturing Services Set to Witness Significant Growth Over Next 10 Years The opportunity to become a market leader in the rapidly growing biosimilar industry has spurred many companies to invest in biosimilar development, either directly or through a partnership with a more experienced CMO. Currently, in 2020, there are over 55 approved biosimilars in the EU and the market for these products is expected to grow rapidly in the coming 10 years. Demand for lower-cost biological therapies in developed and emerging markets, as well as patent expires for blockbuster biologics, will drive investment in biosimilar development. CMOs that can offer expertise and biomanufacturing capacity will benefit from contracts with biosimilar developers, such as small molecule generic drug manufacturers, as well as emerging biosimilar manufacturers looking to launch their follow-on biologics in developed markets. U.S. Holds the Maximum Market Share in Global Biological Drug API Manufacturing Services Market The US is the global leader of the biological drug API manufacturing service market and this is no surprise as it also has the highest level of demand worldwide for pharmaceuticals, including outsourced API manufacturing. Per person, the US spends around one thousand dollars a year on pharmaceuticals, higher than any other country in the world. Additionally, pharmaceuticals cost more in the US, with some drugs being twice the price they are in the UK and Canada. This is because the US government does not regulate its pharma prices. Furthermore, the opaque US health system makes it hard to draw drug-by-drug comparisons with prices abroad. The majority of the leading biotech CMOs have facilities in the United States, which provide APIs domestically. In 2020, US market accounted for US$ xx million, or over 90%, of the North American biological drug API manufacturing services revenues. Emerging markets are no longer as cheap as they used to be and additionally, emerging markets do not always meet quality standards. This deficiency in standards and rise in costs because of the demands for compliance to standards has increased the demand in the US market. Local manufacturers can also provide products more conveniently, as there are less communication or timing issues. Discover how to stay ahead Our 350+ page report provides 350+ tables and charts/graphs. Read on to discover the most lucrative areas in the industry and the future market prospects. Our new study lets you assess forecasted sales at overall world market and regional level. See financial results, trends, opportunities, and revenue predictions. Much opportunity remains in this growing Biological Drug API Manufacturing Services Market. See how to exploit the opportunities. Forecasts to 2031 and other analyses reveal the commercial prospects • In addition to revenue forecasting to 2031, our new study provides you with recent results, growth rates, and market shares. • You find original analyses, with business outlooks and developments. • Discover qualitative analyses (including market dynamics, drivers, opportunities, restraints, and challenges), SWOT Analysis, product profiles and commercial developments. Discover sales predictions for the world market and sub-markets. By Manufacturing Type • Outsourced • In-house By Expression Platform • Mammalian Cell Cultures • Microbial Fermentations • Others By Application • Vaccines • MABs • Insulin Analogues • Interferon Therapies • Human Growth Hormones • Other Therapeutic Areas In addition to the revenue predictions for the overall world market and segments, you will also find revenue forecasts for 5 regional and 22 leading national markets: By Region • North America – U.S. – Canada • Europe – Germany – France – UK – Italy – Spain – Russia – Switzerland – Netherlands – Rest of Europe • Asia Pacific – China – Japan – India – Australia – South Korea – Singapore – Rest of Asia Pacific • Latin America – Brazil – Mexico – Colombia – Argentina – Rest of Latin America • Middle East & Africa – GCC – South Africa – Rest of Middle East & Africa Leading companies and the potential for market growth Overall world revenue for Biological Drug API Manufacturing Services Market will surpass $xx million in 2021, our work calculates. We predict strong revenue growth through to 2031. Our work identifies which organizations hold the greatest potential. Discover their capabilities, progress, and commercial prospects, helping you stay ahead. How the Biological Drug API Manufacturing Services Market report helps you In summary, our 350+ page report provides you with the following knowledge: • Revenue forecasts to 2031 for Biological Drug API Manufacturing Services Market, with forecasts for Manufacturing Type, Expression Platform, and Application, each forecasted at a global and regional level– discover the industry’s prospects, finding the most lucrative places for investments and revenues • Revenue forecasts to 2031 for 5 regional and 22 key national markets– See forecasts for the Biological Drug API Manufacturing Services market in North America, Europe, Asia Pacific, and Rest of the World. Also forecasted is the market in the US, Canada, Brazil, Mexico, Germany, France, UK, Italy, Spain, Russia, Switzerland, Netherlands, China, India, Japan, Australia, South Korea, Singapore, among other prominent economies. • Prospects for established firms and those seeking to enter the market– including company profiles for 10 of the major companies involved in the Biological Drug API Manufacturing Services Market. Some of the company’s profiled in this report include Bristol-Myers Squibb Co., Samsung Biologics, AbbVie, GSK Biopharmaceuticals, Lonza Group Ltd., NEKTAR THERAPEUTICS, Boehringer, Patheon N.V., Cytovance Biologics, and Fujifilm Diosynth Biotechnologies. Find quantitative and qualitative analyses with independent predictions. Receive information that only our report contains, staying informed with this invaluable business intelligence. Information found nowhere else With our newly report title, you are less likely to fall behind in knowledge or miss out on opportunities. See how our work could benefit your research, analyses, and decisions. This study is for everybody needing commercial analyses for the Biological Drug API Manufacturing Services Market and leading companies. You will find data, trends, and predictions.Read the full report: https://www.reportlinker.com/p06058469/?utm_source=GNWAbout ReportlinkerReportLinker is an award-winning market research solution. Reportlinker finds and organizes the latest industry data so you get all the market research you need - instantly, in one place.__________________________ CONTACT: Clare: email@example.com US: (339)-368-6001 Intl: +1 339-368-6001
People returning from holidays in ‘green’ countries will not be required to self-isolate under the new traffic light system.
Toshiba's board planned to oust troubled CEO Nobuaki Kurumatani before CVC Capital Partners launched a $20 billion buyout bid last week, informing him a day before the offer was announced that it would replace him, people familiar with the matter said. Two members of Toshiba Corp's nomination committee, including board chairman Osamu Nagayama, met Kurumatani, himself a former CVC executive, and told him they intended to look for a new chief executive, three of the people said. Kurumatani then told them of the European private equity firm's plan to take Toshiba private, the three people said.
The "Drafting Commercial Contracts Training Course" training has been added to ResearchAndMarkets.com's offering.
Euro zone citizens expect the European Central Bank's proposed digital euro to be private, safe and cheap, an ECB survey showed on Wednesday. The ECB is working on creating an electronic form of cash to complement banknotes and coins in a bid to stem competition from cryptocurrencies such as Bitcoin, Tether and Facebook’s proposed Diem. An ECB poll showed that privacy when making payments, a key feature of cash that some fear will get lost when switching to an electronic means of payment, was the number one priority for both private individuals and professionals.
LVMH's shares rose to record highs on Wednesday after the world's biggest luxury goods company posted sales figures that showed it had bounced back far more quickly than expected in early 2021. LVMH shares were up by 2.7% in early session trading, hitting new record levels, and also lifting up the shares of rival luxury goods companies such as Kering and Hermes. Late on Tuesday, LVMH posted first-quarter revenues that even exceeded 2019 levels, before the pandemic.
Joining the new Sandero is a chunkier Stepway version, but is it worth choosing over the standard car? Ted Welford finds out.
US political developments, as they happen
The 19-year-old looked set to leave the club when his current contract expires this summer
(Bloomberg) -- Egypt seized a giant container vessel that blocked the Suez Canal last month as talks continued over the more than $900 million in compensation sought by authorities.A court in the city of Ismailia granted a seizure request regarding the Ever Given vessel at the behest of the Suez Canal Authority, state-run Ahram Gate reported Tuesday on its website.Egypt’s move underscores the legal complications following the container vessel’s grounding on March 23, which closed the canal for almost a week and roiled shipping markets. Logjams are expected to continue in the coming weeks at major ports such as Singapore and Rotterdam because of disruptions to schedules, according to supply-chain data provider project44.The Suez Canal Authority’s chief executive officer, Osama Rabie, told an Egyptian TV channel late Tuesday that negotiations with the ship’s owners and insurers were taking longer than anticipated, especially given the vessel and its containers were undamaged.The ship’s insurer for third-party losses, the U.K. P&I Club, said in a statement on Tuesday that the Ever Given’s owner -- Japan-based Shoei Kisen Kaisha Ltd. -- received a claim for $916 million.“Despite the magnitude of the claim which was largely unsupported, the owners and their insurers have been negotiating in good faith with the SCA,” the statement said. “On 12 April, a carefully considered and generous offer was made to the SCA to settle their claim. We are disappointed by the SCA’s subsequent decision to arrest the vessel today.”The U.K. P&I Club also said it was “disappointed at comments by the SCA that the ship will be held in Egypt until compensation is paid, and that her crew will be unable to leave the vessel during this time.”Loss of FeesThe SCA has said compensation is needed to cover losses of transit fees, damage to the waterway during the dredging and salvage efforts, and the cost of equipment and labor. It has calculated that it missed out on about $15 million of transit fees each day.The U.K. P&I Club said the claim included a $300 million salvage bonus and another $300 million for loss of reputation.“The claim presented by the SCA also does not include the professional salvor’s claim for their salvage services which owners and their hull underwriters expect to receive separately,” the U.K. P&I Club said. “The grounding resulted in no pollution and no reported injuries. The vessel was re-floated after six days and the Suez Canal promptly resumed their commercial operations.”Negotiations will continue, it said. The SCA didn’t respond to requests for comment.The SCA’S CEO, speaking to Egypt’s Mehwar TV channel, said the owners and insurers “didn’t say when or what they’ll pay” and hadn’t mentioned specific figures.“We sent them a figure, they said we want a breakdown,” Rabie said. “We sent the breakdown, they said we want a detailed one. We sent them a detailed breakdown, but so far nothing.”Rabie stressed again that seizing the Ever Given is a legal procedure that would be lifted as soon as there’s payment.A spokesman for Shoei Kisen Kaisha declined to comment on compensation while discussions with the SCA are underway. The company said the crew is still on board the ship, which is now in the Great Bitter Lake, about halfway along the canal.The charterer, Taiwan’s Evergreen Marine Corp., said in an email it hadn’t received any information from the ship’s owner about a court order.For more articles like this, please visit us at bloomberg.comSubscribe now to stay ahead with the most trusted business news source.©2021 Bloomberg L.P.
All the contenders to be the mystery relative
Israel marked its national Memorial Day for fallen soldiers on Wednesday, in a year when national attention has been focused on the plight of veterans suffering from psychological trauma. Memorial Day is the most solemn day on Israel's national calendar. Israel has fought half a dozen wars with neighboring Arab countries, battled two Palestinian uprisings and endured scores of deadly militant attacks since its establishment in 1948.
Forecasts by Service (Process Development (Downstream, Upstream), Fill & Finish Operations, Analytical & Quality Control Studies, Packaging), by Product (Biologics (Monoclonal Antibodies (mAbs), Recombinant Proteins, Vaccines, Insulin), Biosimilars) Plus Analysis of Leading Companies.New York, April 14, 2021 (GLOBE NEWSWIRE) -- Reportlinker.com announces the release of the report "Biopharmaceuticals Contract Manufacturing Market Report 2020-2030" - https://www.reportlinker.com/p06058471/?utm_source=GNW Market Dynamics • Continuing expansion of biopharmaceutical manufacturing capacity by CDMOs/CMOs • Increasing outsourcing of biopharmaceuticals-related manufacturing activities • Increasing demand for fill-finish services in biopharmaceutical contract manufacturing market • Increasing productivity and efficiency of biopharmaceuticals manufacturing processes • Uptake of single-use production systems by the biopharmaceutical manufacturing industry • Asia emerging as hot destination for biopharmaceutical manufacturing • Increasing confidence of pharmaceutical industry in CDMOs capabilities • High level of outsourcing of manufacturing newly approved drugs by smaller biotech companies is fueling the growth of biopharma-specific CMOs/CDMOs • Higher acceptance and success of biopharmaceutical products in the market provides tremendous opportunities to biopharmaceuticals contract manufacturers • Increasing shortage of skilled workforce in the biopharmaceutical industry • Expensive manufacturing equipment requirements and complex processes raise barriers to entry, which is limiting market growth • Complicated and stringent regulatory requirements hinder market growth Market Segmentation 2020-2030 Biopharmaceuticals Contract Manufacturing Market is segmented on the Service, Product, and Regional basis. Service • Process Development – Downstream – Upstream • Fill & Finish Operations • Analytical & Quality Control Studies • Packaging Product • Biologics – Monoclonal Antibodies (MAbs) – Recombinant Proteins – Vaccines – Insulin • Biosimilars Regional Breakdown Focused regional forecasts and analysis explore the future opportunities: • North America – U.S. – Canada • Europe – UK – France – Germany – Russia – Rest of Europe • Asia-Pacific – China – Japan – India – Southeast Asia – Rest of Asia Pacific • Latin America – Brazil – Argentina – Rest of Latin America • Middle East & Africa – GCC – South Africa – Rest of Middle EastRead the full report: https://www.reportlinker.com/p06058471/?utm_source=GNWAbout ReportlinkerReportLinker is an award-winning market research solution. Reportlinker finds and organizes the latest industry data so you get all the market research you need - instantly, in one place.__________________________ CONTACT: Clare: firstname.lastname@example.org US: (339)-368-6001 Intl: +1 339-368-6001
Her Instagram post featured a teaser on the Countdown board.
Expert thinks footprint could belong to Megalosaurus
China's special climate envoy, Xie Zhenhua, will meet with his U.S. counterpart John Kerry in Shanghai this week and exchange views on a key United Nations climate conference, the foreign ministry said on Wednesday. High-level talks in Alaska last month, the first since U.S. President Joe Biden took office, yielded no breakthrough. Kerry, who Biden selected to represent the United States in international climate talks, will seek to find common ground on climate change with Xie, whom he has been acquainted with for years.